• Nov 20
    Cancer Biology Seminar Series: Marina Sharifi, MD, PhD

    1345 HSLC

    Leveraging liquid biopsies to track mechanisms of targeted therapy resistance in breast and prostate cancer Marina Sharifi, MD, PhD Assistant Professor, Hematology, Medical Oncology and Palliative Care University of Wisconsin–Madison

  • Nov 13
    Cancer Biology Seminar Series: Ping Chi, MD, PhD

    1345 HSLC

    Harnessing innate immunity in sarcoma Ping Chi, MD, PhD Associate Professor, Cell & Developmental Biology Weill Cornell School of Medicine Memorial Sloan Kettering Cancer Center

  • Nov 6
    Cancer Biology Seminar Series: Nicholas Wallace, PhD

    1345 HSLC

    Targeting HPV Oncogene-Induced Alterations in Cervical Cancer Nicholas Wallace, PhD Professor, Division of Biology Johnson Cancer Research Center Kansas State University

  • Oct 30
    Cancer Biology Seminar Series: Dechen Lin, PhD

    1345 HSLC

    Organoid modeling cancer evolution and drug response Dechen Lin, PhD Assistant Professor, Herman Ostrow School of Dentistry University of Southern California

  • Oct 23
    Cancer Biology Seminar Series: Binhua Zhou, MD, PhD

    1345 HSLC

    TBD Binhua Zhou, MD, PhD Professor, Molecular and Cellular Biochemistry University of Kentucky School of Medicine

  • Oct 16
    Cancer Biology Seminar Series: Mohamed Abazeed, MD, PhD

    1345 HSLC

    Harnessing computation to guide more individualized cancer therapies to the lung Mohamed Abazeed, MD, PhD Associate Professor, Radiation Oncology Northwestern University

  • Oct 9
    Cancer Biology Seminar Series: Charles Perou, PhD

    1345 HSLC

    Quantitative Medicine for Breast Cancer Patients Charles Perou, PhD Professor of Molecular Oncology University of North Carolina School of Medicine

  • Oct 2
    Cancer Biology Seminar Series: Todd Stukenberg, PhD

    1345 HSLC

    Mechanisms of Chromosomal Instability in Breast Cancer Todd Stukenberg, PhD Professor, Biochemistry and Molecular Genetics University of Virginia School of Medicine

  • Sep 25
    Cancer Biology Seminar Series: Dave Vereide, PhD

    1345 HSLC

    Arming induced pluripotent stem cells with a synthetic receptor enables the scalable manufacture of highly cytotoxic lymphocytes for “off-the-shelf” cancer immunotherapies Dave Vereide, PhD Principal Scientist Umoja Biopharma

  • Sep 18
    Cancer Biology Seminar Series: Dusty Deming, MD

    1345 HSLC

    Future Strategies for Precision Targeting of Cancer Therapeutics Dusty Deming, MD Associate Professor of Hematology-Oncology University of Wisconsin–Madison